Tonix Pharmaceuticals (TNXP) Downgraded by ValuEngine
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Sunday.
Separately, Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $8.33.
Tonix Pharmaceuticals (TNXP) opened at $3.45 on Friday. Tonix Pharmaceuticals has a 52-week low of $2.85 and a 52-week high of $9.40. The stock has a market capitalization of $26.91, a price-to-earnings ratio of -0.72 and a beta of 2.92.
A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Vanguard Group Inc. raised its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 184,377 shares of the company’s stock after acquiring an additional 41,264 shares during the period. Vanguard Group Inc. owned about 2.46% of Tonix Pharmaceuticals worth $799,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.57% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/01/tonix-pharmaceuticals-tnxp-downgraded-by-valuengine.html.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.